Fibroblast activation protein inhibitor is a promising diagnostic agent that allows the imaging of numerous malignancies. Although it targets cancer-associated fibroblasts, it also shows uptake in normal activated fibroblasts involved in inflammation or fibrosis.

This talk will explore FAPI uptake patterns following invasive medical interventions to aid diagnosticians in correctly identifying potential false-positive imaging pitfalls.

Learning Objectives: 

– Identity interventions that may potentially cause false positive FAPI uptake.

– Identify factors that influence the presence or absence of FAPI uptake at intervention sites.

– Recognize the differences in uptake patterns whether interventions have foreign body placement or not.

– Compare FAPI tracer uptake at intervention sites to other tracers (FDG, PSMA)

Presenter Biography:
Peter George Maliha, MD, FRCPC is a nuclear medicine physician at the Centre Hospitalier de l’Université de Montréal since July 2023. He is engaged in research, including 225Ac-PSMA therapy, and plays a significant role in directing the nuclear medicine program of the Université de Montréal. He co-created a preceptorship program for 177Lu-PSMA and DOTATATE therapy and is a proud board member of the Canadian Association of Nuclear Medicine since 2022. His experience on FAPI PET/CT imaging was developed during his fellowship training at the University of California in Los Angeles. There, he contributed to four case reports on incidental non-cancer findings, serving as the first author on three. He was also first author of a short communication on normal variant FAPI tracer uptake in the epididymis and of a manuscript on FAPI PET uptake patterns after invasive medical interventions.

Author